Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Equity Average (2016 - 2025)

Historic Equity Average for Intellia Therapeutics (NTLA) over the last 10 years, with Q3 2025 value amounting to $731.8 million.

  • Intellia Therapeutics' Equity Average fell 2430.6% to $731.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $731.8 million, marking a year-over-year decrease of 2430.6%. This contributed to the annual value of $961.1 million for FY2024, which is 1590.85% down from last year.
  • As of Q3 2025, Intellia Therapeutics' Equity Average stood at $731.8 million, which was down 2430.6% from $747.6 million recorded in Q2 2025.
  • Intellia Therapeutics' 5-year Equity Average high stood at $1.2 billion for Q1 2023, and its period low was $520.3 million during Q2 2021.
  • For the 5-year period, Intellia Therapeutics' Equity Average averaged around $917.9 million, with its median value being $966.8 million (2024).
  • Its Equity Average has fluctuated over the past 5 years, first soared by 15065.51% in 2021, then crashed by 2550.94% in 2025.
  • Over the past 5 years, Intellia Therapeutics' Equity Average (Quarter) stood at $1.1 billion in 2021, then decreased by 4.04% to $1.0 billion in 2022, then rose by 1.31% to $1.0 billion in 2023, then decreased by 12.12% to $917.3 million in 2024, then dropped by 20.22% to $731.8 million in 2025.
  • Its Equity Average was $731.8 million in Q3 2025, compared to $747.6 million in Q2 2025 and $825.9 million in Q1 2025.